"High profitability and launch preparations for Oczyesa^®"

Summary third quarter 2025

July - September

• Total revenues grew 18% (25% at CER¹) to SEK 567 (480) million
• Sales of Buvidal^® increased 8% (15% at CER¹) to SEK 455 (421) million
• Brixadi^® royalties increased 91% (100% at CER¹) to SEK 111 (58) million
• Profit before tax increased 48% to SEK 245 (165) million
• The cash position at the end of the quarter was SEK 3.5 (2.8) billion
• Oczyesa^® (CAM2029) approved in the UK for the treatment of acromegaly
• FDA and the European Commission granted orphan drug designation for CAM2029 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
• Anders Vadsholt assumed the role as Camurus' new CFO

January - September

• Total revenues grew 37% to SEK 1,801 (1,314) million
• Sales of Buvidal increased 19% (23% at CER1) to SEK 1,409 (1,185) million
• Brixadi royalties increased 113% to SEK 274 (129) million
• Profit before tax increased 120% to SEK 806 (366) million
• Financial outlook 2025 updated: Guidance for total revenues lowered to SEK 2.3-2.6 billion from SEK 2.7-3.0 billion. Profit before tax maintained at SEK 0.9-1.2 billion.

Financial summary third quarter 2025

• Total revenues SEK 567 (480) million
  - whereof product sales SEK 455 (421) million, and royalties SEK 111 (58) million
• OPEX SEK 298 (304) million
• Operating result SEK 230 (142) million
• Profit before tax SEK 245 (165) million
• Result for the period SEK 193 (129) million
• Earnings per share, after dilution, SEK 3.19 (2.16)

• Cash position SEK 3,515 (2,751) million

1) At constant exchange rate

Fredrik Tiberg, President and CEO:
"Camurus had a robust third quarter with increased revenues and high profitability. Royalties from the sales of Brixadi^® in the US contributed to growth, while the performance in Europe was weaker. Oczyesa^® received a second regulatory approval for the treatment of acromegaly, and was recently launched in Germany as the first market in Europe. The NDA for Oclaiz™ in the US is ready for resubmission to the FDA, pending completion of an ongoing inspection at the contract manufacturer. Within our development portfolio, the Phase 3 study SORENTO of CAM2029 progressed in patients with neuroendocrine tumors alongside a Phase 1b study of CAM2056, semaglutide monthly depot, in participants with overweight or obesity. Topline results for CAM2056 are expected shortly."

Webcast
Financial analysts, investors and media are invited to attend a webcast and presentation of the results at 2.00 pm CET.

Access the webcast using this link: https://camurus.events.inderes.com/q3-report-2025

To participate in the presentation and ask questions, please register using the link below. After registering, please use the provided phone number and conference ID to dial in: https://events.inderes.com/camurus/q3-report-2025/dial-in

For more information:
Fredrik Tiberg, President and CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal^® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.

This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation and to the Securities Markets Act. The information was submitted for publication, through the agency of the chief executive officer, at 07.00 am CET on 6 November, 2025.